CURRICULUM VITAE DR. ADINA MAZILU
|
|
- Dale Newton
- 5 years ago
- Views:
Transcription
1 CURRICULUM VITAE DR. ADINA MAZILU POZITIE ACTUALA: medic primar Endocrinologie din prezent medic specialist Diabet zaharat, Nutritie si Boli metabolice din 2013-prezent angajata a S.U.U.M.C Dr. Carol Davila Sectia Endocrinologie competenta in Ecografia glandelor endocrine si Sexologie diploma de Certified Clinical Densitometrist experienta in DXA-operare si interpretare DXA din 2008 responsabil cu Nutritia in cadrul SUUMC Dr. Carol Davila responsabil de Management infectii nosocomiale in cadrul Sectiei Endocrinologie a SUUMC Dr. Carol Davila curs de Prim ajutor medical specializat 2000 si curs de Radioprotectie 2016 COMPETENTE PERSONALE: LB. ENGLEZA- NIVEL C1 LB. FRANCEZA- NIVEL C1 PARTICIPARE LA EMISIUNI TELEVIZATE-FRESH REFRESH-REALITATEA TV-2016, B1 TV, TVR 1, Kanal D STUDII CLINICE MULTICENTRICE - SUBINVESTIGATOR A long-term study of sibutramine and the role of obesity management in relation to cardiovascular disease in overweight and obses patients (SCOUT), trial de faza III, Sponsor- Abbott, directorul studiului Cheryl Renz, MD ROADMAP, (Randomized Olmesartan an Diabetes microalbuminuria Prevention Study)trial de faza III. n caltr als.gov/show/nct Sponsor Sankyo Pharma Gmbh PLANET 1 (D3569C00007)- Randomised, Double-blind, 52-wk, Parallelgrp, Multicentre, PIIb Study to Evaluate Effects of Rosuvastatin 10mg, Rosuvastatin 40mg and Atorvastatin 80mg on Urinary Protein Excretion in Hypercholesterolaemic Diabetic Patients With Moderate Proteinuria,trial faza II, Sponsor Astra Zeneca Protocol 306A1-300-EUA Multicenter, Double Blind, Randomized, Placebo and Raloxifene Controlled Study to Assess Safety and Efficacy of TSE-424 (Bazedoxifene Acetate) in the Prevention of Postmenopausal Osteoporosis, trial de faza III, Wyeth Research Protocol 3047K5-319-WWA Multicenter, Randomized, Double-Blind, Comparison Study of the Safety and Efficacy of a Once-Daily Dose of Tigecycline Versus Ertapenem for the Treatment of Foot Infections in Subjects With Diabetes. n caltr als.gov/ct2/show/studv/nct Wyeth Research International, Multi-center Post Authorization Surveillance Study on the Use of Nebido to Assess Tolerability and Treatment Outcomes in Daily Clinical Practice (IPASS Nebido), trial de fazaiii. n caltr als.gov/ct2/show/nct Sponsor Bayer Protocol 3068A1-301-WW: Fracture Incidence Reduction And Safety Of TSE-424 (Bazedoxifene Acetate) Compared To Placebo And Raloxifene In Osteoporotic Postmenopausal Women, trial de faza III, Wyeth Research ,A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate Cardiovascular Outcomes During Treatment With Lixisenatide in Type 2 Diabetic Patients After an Acute Coronary Syndrome (ELIXA)- studiuclinic multinational, multicentric de faza III, sindroame coronare acute, , sponsor Sanofi-Aventis
2 A Phase IIIB study to evaluate the potential of Aleglitazar to reduce cardiovascular risk in patients with stable cardiovascular disease and glucose abnormalities; ; trial de faza IIIB; Sponsor Hoffman-LaRoche A Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Add-On Therapy With Saxagliptin and Dapagliflozin Added to Metformin Compared to Add-On Therapy With Saxagliptin in Combination With Metformin or Dapagliflozin in Combination With Metformin in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone; MB Study; trial de faza III; Sponsor Bristol-Myers Squibb 2012-prezent A Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Triple Therapy With Saxagliptin Added to Dapagliflozin in Combination With Metformin Compared to Therapy With Placebo Added to Dapagliflozin in Combination With Metformin in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin and Dapagliflozin; stdiu de faza III multicentric, multinational: ; Sponsor Bristo- Myers Squibb Company 2012-prezent A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Therapy With Dapagliflozin Added to Saxagliptin in Combination With Metformin Compared to Therapy With Placebo Added to Saxagliptin in Combination With Metformin in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin and Saxagliptin; studiu clinic de faza III multicentric, multinational; ; Sponsor Bristol-Myers Squibb Company A Phase IIIB study to evaluate the potential of Aleglitazar to reduce cardiovascular risk in patients with stable cardiovascular disease and glucose abnormalities; ; trial de faza IIIB; Sponsor HoffmanLaRoche 2013-prezent Phase 3 Multi Center, Double Blind, Randomized, Placebo Controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of PF , In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects; studiu clinic de faza III; ; Sponsor Pfizer A Randomised, Double Blind, Placebo Controlled, Parallel Group, Dose Ranging Study of GWP42004 as Add on to Metformin in the Treatment of Participants With Type 2 Diabetes; ; Sponsor GW Pharmaceuticals 2013-prezent A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Parallel- Group Study To Assess The Efficacy, Safety And Tolerability Of Pf In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events; ; sponsor Pfizer prezent A Randomized, 30 Week, Active-controlled, Open-label, 3-treatment Arm, Parallelgroup Multicenter Study Comparing the Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination to Insulin Glargine Alone and to LixisenatideAlone on Top of Metformin in Patients With Type 2 Diabetes Mellitus T2DM; ; sponsor Sanofi Aventis 2014-prezent A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy, ; sponsor Janssen research and Developpment, LLC 2015-prezent A multicenter, randomized, double-blind, placebo-controlled, parallel group, phase 3 trial to evaluate the safety and efficacy of once weekly Exenatide
3 therapy added to titrated Basal Insulin Glargine compared to placebo added to titrated Basal Insulin Glargine in patients with type 2 diabetes who have inadequate glycemic control on Basal Insulin Glargine with or without Metformin; sponsor Astra Zeneca 2015-prezent A 28-week, Multicenter, Randomized, Double-Blind, Active- Controlled, Phase 3 Study With a 24-week Extension Phase Followed by a 52-week Extension Phase to Evaluate the Efficacy and Safety of Simultaneous Administration of Exenatide Once Weekly 2 mg and Dapagliflozin Once Daily 10 mg Compared to Exenatide Once Weekly 2 mg Alone and Dapagliflozin Once Daily 10 mg Alone in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin; ; sponsor Astra Zeneca CURSURI DE PERFECTIONARE Cursurile Postuniversitare ETA (European Thyroid Association),Poiana Brasov, Al XV lea Congres National de Endocrinologie,Asociatia Romana de Endoccrinologie, European Thyroid Association GCP Training Complinace, Bucharest, Romania Cursuri de 12 saptamani pentru Competenta de Sexologie Curs de radioprotectie Nivel 2 PREZENTARI LA MANIFESTARI STIINTIFICE INTERNE: Simpozion Terapii inovatoare in osteoporoza- primii doi ani de experienta si concluzii; Congresul Nationala de Endocrinologie cu Participare Internationala, ed XXI, Reductil presentations- Abbott Prezentari pentru compania Abbott, Amgen, MSD LUCRARI STIINTIFICE CONGRESE: 1. Micro- si macroprolactinoamele sunt două boli distincte? Diagnostic - Congresul European de Endocrinologie - Torino, Italia, 9-13 iunie Consequences of belated treatment in primary mixedema- AE Ranetti, N Diaconu, C Spiroiu, C Dumitrache, S Blaj, V Mihalache, M Flueras, A Onofrei;poster presentation, 5th European Congress of Endocrinology, , Turin Italy, rezumat publicat in volumul de rezumate al congresului 3. Efectele Sibutiraminei asupra profilului lipidic; Dr A.E. Ranetii, Dr. Adina-Onofrei- Mazilu, Congresul National Obezitatea si bolile asociate, Cluj Hiperparatiroidismul secundar la femeile în postmenopauză - incidentă, aspecte clinice, implicatii terapeutice; Dr. A. Ranetti, dr. N.Diaconu, Dr. C.Spiroiu, dr. Ana- Maria Mihai, Dr. Adina Mazilu - CongresulNational de Endocrinologie - Craiova, 5-7iunie Tiroidita cronică autoimună asociată cu alte boli autoimune; Dr. A. Ranetti, dr. N.Diaconu, Dr. C.Spiroiu, dr. Ana-Maria Mihai, Dr. Adina Mazilu - Congresul National de Endocrinologie - Craiova, 5-7 iunie Consideratii terapuetice privind disfunctia erectila la pacientii diabetici- AE Ranetti, C Spiroiu, AM Mihai, N diaconu, A Mazilu; Al 29lea congres national de diabet, nutritie si boli metabolice cu particpare internationala, mai 2003, Craiova, rezumat publicat in Acta diabetologica Romana, vol XXIX Aspecte etiopatogenice si clinico-evolutive ale unor forme secundare de diabet zaharat; dr. A.E. Ranetti, dr. C.Spiroiu,dr. A.Mihai, dr. A.Mazilu; Al 29lea congres national de diabet, nutritie si boli metabolice cu particpare internationala, mai 2003, Craiova, rezumat publicat in Acta diabetologica Romana, vol XXIX Endocrinological features of atrial fibrillation; dr. A.E. Ranetti, dr.c.spiroiu,dr.a.mihai,dr.a.mazilu; 8th Congress of Balkan Military Medical Committee, 2124 sept 2003, Cluj Napoca, Romania, Rezumat publicat in volumul de rezumate al congresului
4 9. Clinical and pathological aspects of some secondary forms of diabetes mellitus; dr. A.E. Ranetti, dr. C.Spiroiu, dr. A.Mihai, dr.a.mazilu; 8th Congress of Balkan Military Medical Committee, sept 2003, Cluj Napoca, Romania, Rezumat publicat in volumul de rezumate al congresului 10. Feocromocitomul malign bilateral - prezentare atipică - ENEA -Sorrento, Italia, aprilie Tiroidita subacută si bicitopenia după terapia cu interferon 2-a administrat în hepatite - ENEA - Sorrento, Italia, aprilie Poliglandular autoimmune syndrome associated with meningioma; dr. A.E. Ranetti, dr. C.Spiroiu, A.Mihai, A.Mazilu;Congresul Balcanic de Medicină Militară, Istanbul, iunie Management of thyroid cancer in children - 5 years experience; dr. A.E. Ranetti, dr. C.Spiroiu, dr. A.Mihai, dr. A.Mazilu;Congresul Balcanic de Medicină Militară, Antalya, iunie Particularităti evolutive în carcinomul papilar tiroidian; dr.a.mazilu, dr.a.e.ranetti,r.mititelu,gmarinescu,prof.dr.codorean;congresul National de Endocrinologie,Timisoara, Modificări psihice la o serie de pacienţi cu boală Graves-Basedow -Congresul National de Neuroendocrinologie-Poiana Brasov, 3-6 iunie Sindromul depresiv în hiperprolactinemii - Congresul National de Neuroendocrinologie - Poiana Brasov, 3-6 iunie Dificultăţi de diagnostic în insulinoame - Congresul National de Neuroendocrinologie - Poiana Brasov, 3-6 iunie Pollyglandular autoimmune syndrome associated with meningioma.adina Mazilu,., Ana- Maria Mihai, Cristina Spiroiu., Lt-Col. A.E.Ranetti, 9th Congress of Balkan Military Medical Committee,21-24 June 2004, Antalya, TURKEY Abstract published in Balkan Military Medical Review 19. The efficacy of levothyroxine therapy in the nontoxic multinodular goiter,a.e.ranetti C Spiroiu, Am. Mihai, A. Mazilu, C. Ranetti Pharmacist, C.Stefan. D Mihai. 9th Congress ofbalkan Military Medical Committee,21-24 June 2004, Antalya, TURKEY 20. Follow-up of fibrocystic mastosis In postmenopausal women; Adina Mazilu, Ana- Maria Mihai, Cristina Spiroiu.,Lt-Col. A.E.Ranetti, 9th Congress ofbalkan Military Medical Committee,21-24 June 2004, Antalya, TURKEY, 21. Prevalence of the metabolic syndrome in overweight adults. Adina Mazilu,, Ana- Maria Mihai, Cristina Spiroiu, Lt-Col. A.E.Ranetti, M. Costin, 9th Congress of Balkan Military Medical Committee,21-24 June 2004, Antalya, TURKEY Abstract published in Balkan Military Medical Review 22. A rare form of secondary osteoporosis - osteogenesis imperfecta - Case Report - C. Spiroiu, A.E.Ranetti, N. Diaconu, A. Popescu, A. Mazilu, A.M. Mihai, Cpt. C. Ranetti, Pharm., 9th Congress ofbalkan Military Medical Committee,21-24 June 2004, Antalya, TURKEY; 23. Ulceration in diabetic foot - Dr. N. Diaconu. Dr. A.E.Ranetti. Dr. C. Spiroiu, Dr. Ana-Maria Mihai, Pharm. Cristina Ranetti, Dr. Adina Mazilu, 9th Congress of Balkan Military Medical Committee,21-24 June 2004, Antalya, TURKEY Abstract published in Balkan Military Medical Review 24. Consecinte ale patologiei endocrine in stomatologie, Congresul International de Stomatologie, 8-11 martie 2005, Bucuresti, Romania; A.E. Ranetti, C.Spiroiu, A. Mazilu,A.M. Mihai 25. Sibutiramine efficiency in metabolic control of obese diabetic patients- A Mazilu, A Mihai, C Spiroiu, AE Ranetti, oral presentation, 14th European Congress on Obesity Pregnancies in women with premature ovarian failure. A.E.Ranetti; A.M. Mihai; C.Spiroiu; A.Mazilu - The 13th Balkan Congress of Endocrinology, October 2005, Bucharest, Romania; Abstract published in Balkan Military Medical Review
5 27. Papillary thyroid carcinoma with invasion in the medullary canal T1 - T2 - A.E.Ranetti; A.M. Mihai; C.Spiroiu; A.Mazilu- The13th Balkan Congress of Endocrinology, October 2005, Bucharest, Romania; 28. The efficacy of levothyrooxine therapy in the nontoxic multinodular goiter- AM Mihai, AE Ranetti, C Spiroiu, A Mazilu,C Ranetti, poster presentation, 8th european Congress of Endcorinology incorporating the British Endocrine Societies, abstract published in 'Endocrine Abstracts, ISSN (print), ISSN (on-line), volume 11, april 2006, 1-5 april 2006, Glasgow, UK 29. Management of thyroid cancer in children- A Mazilu, AE Ranetti, A Mihai, C spiroiu, poster presentation, 8th european Congress of Endcorinology incorporating the British Endocrine Societies, abstract published in Endocrine Abstracts, ISSN (print), ISSN (on-line), volume 11, april 2006, 1-5 april 2006, Glasgow, UK 30. Diagnosis difficulties in insulinomas. AE Ranetti,A.Mazilu, C. Spiroiu & A.Mihai - 8th european Congress of Endocrinology incorporating the British Endocrine Societies, 1-5 April, 2006 Glasgow, UK; 31. Implicatiile cavitatii bucale in relatiile de cuplu. Ranetti A.E., Spiroiou C., Mazilu A., Mihai A.M. - A VI a Conferinta Nationala de Medicina Sexualitatii, martie 2006, Bucuresti, rezumat publicat in volumul de rezumate al congresului. 32. Obesity and sexual life in men, A.E. Ranetti, A. Mazilu, C. Spiroiu, AM. Mihai, International Congress on Obesity, 3-8 Sept. 2006, Sydney, Australia, 33. Paraneoplastic Cushing's syndrome presenting as psychosis - case report, Cristina Spiroiu, A.E. Ranetti, Ana Maria Mihai, Adina Mazilu, N. Diaconu, 9th European Congress of Endocrinology, 28-apr.-02 may 2007, Budapest, 34. Sexualitatea si menopauza. Ana Maria Mihai, A.E.Ranetti, Cristina Spiroiu, N. Diaconu, Adina Mazilu - Al XIV-lea Simpozion National de Psihoneuroendocrinologie, mai2007, Sibiu, 35. Sibutramine efficency in metabolic control of obese diabetic patients, A. Mazilu, A.Mihai, C. Spiroiu, A.E. Ranetti, 14th European Congress on Obesity, 1-4 June 2005, Athens, 36. Sindrom Cushing paraneoplazic cu debut psihotic. Spiroiu C., Ranetti A.E., Mazilu A., Mihai A.M.; 12th Congress of Balkan Military Medical Committee, June 24-28, 2007, Poiana Brasov, Romania; 37. Hipotiroidism cu debut psihotic mixedem madness - prezentare de caz. Spiroiu C., Ranetti A.E., Mazilu A., Mihai A.M., Vasile D., Tudor C., Vasiliu O.; 12th Congress of Balkan Military Medical Committee, June 24-28, 2007, Poiana Brasov, Romania 38. Effects of sibutramine and other therapies on erectile dysfunction in diabetic patients, A.E. Ranetti, C.Spiroiu, A. Mazilu, 16th European Congress on Obesity, may2008,geneva, 39. Mullerian anomalies in medical practice uterusdidelphys with cervix and double vagina on a patient with PCOS. Case presentation- T Raluca, S. Cristina, AE Ranetti, M. Enyedi, A. Mazilu; Al XI-lea Congres Al Societatii Anatomistilor din Romania, Constanta, poster 40. Detectia tumorilor carcinoide prin imagistica de fuziune PET-CT, A Mazilu, C Mazilu, G Ionescu, Al VXI lea simpozion National de Psihoneuroendocrinologie, mai 2010, Poiana Brasov 41. Ficatul gras non-alcoolic si microalbuminuria la pacientii cu diabet zaharat tip 2 ; C. Constantin, C. Spiroiu, A. Mazilu, G Constantin, N. Diaconu, A.E. Ranetti, Congresul national de endocrinologie 2012, Bucuresti, Palatul Parlamentului 42. Non-alcoholic fatty liver si microalbuminuria la pacientii cu diabet zaharat tip II- C.Constantin, C Spiroiu, A Mazilu, G Constantin, N Diaconu, V Cristescu, AE Ranetti, Simpozionului Zilele Spitalului Universitar de Urgenţă Militar Central Dr. Carol Davila octombrie 2012,Bucuresti; Rezumat publicat in Revista de Mediana Militara,2012, ISSN , indexata CNCSIS C 43. Hyperthyroidism refractory to antithyroid drugs- case report- A. Mazilu, AE Ranetti, prezentare poster PP114; 18th Congress of the Balkan Military Medical
6 Committee, 2012,May 29th - June 1st, Istanbul, Turkey. Rezumat publicat in Balkan Military Medical Review,2013, 16(3):238; e-issn ; 44. Terapii inovatoare in osteoporoza- A.Mazilu, C. Spiroiu, AM Munteanu, N. Diaconu, AE Ranetti; Prezentare orala la Prima Conferinţă de medicină militară şi cea de-a treia ediţie a Simpozionului Zilele Spitalului Universitar de Urgenţă Militar Central Dr. Carol Davila octombrie 2013,Bucuresti; Rezumat publicat in Revista de Medicina Militara 45. ECE Congress 2015-A challenging case of paraneoplastic Cushing's syndrome Adina Mazilu; Mona Gheorghiu; Madalina Musat; Aurelian-Emil Ranetti; Victor - Catalin Mazilu; Narcis Tanase; Razvan Petrescu; Published: ECE 2016-Munich -Malignant giant pituitary tumor- Adina Mazilu-EP Nutritional approach in late gastric stenosis after gastric sleeve, Adina Mazilu, M.D., Dept.of Endocrinology and Metabolism, Central Military Emergency Hospital,Revista de Medicina Militara
CURRICULUM VITAE. Nume: SPIROIU Prenume: CRISTINA
CURRICULUM VITAE Nume: SPIROIU Prenume: CRISTINA Data si locul naşterii:, Bucureşti Loc de munca: Spitalul Universitar de Urgenta Militar Central Dr. Carol Davila, secţia Endocrinologie Limbi străine:
More informationPetrescu Bogdan Mircea
Petrescu Bogdan Mircea Pregătire profesională 2000-2006, Universitatea de Medicină şi Farmacie "Carol Davila" Bucureşti, Facultatea Medicină Generală, Licenta 2006 2013 - Medic specialist psihiatru Funcții
More informationCURRICULUM VITAE. Vereanu Anca Delia. Adresa: Str. Erou Iancu Nicolae 67 B, Data nasterii : 31 iulie Nationalitatea : Romana
CURRICULUM VITAE Vereanu Anca Delia Adresa: Str. Erou Iancu Nicolae 67 B, Vila 7, Voluntari, Ilfov Data nasterii : 31 iulie 1967 Nationalitatea : Romana Statut civil: Casatorita Telefon mobil: +40 722
More informationSpitalul Clinic Judetean de Urgenta str Clinicilor 3-5, , Cluj Napoca (Romania)
Europass Curriculum Vitae Informatii personale Nume, Prenume (Nume anterior casatoriei: Padure ) Adresa Str. C.A.Rosetti, Nr. 16, Cluj Napoca (Romania) Telefon 0040745459080 E-mail(s) munteana2@yahoo.com
More informationLISTA DE LUCRĂRI PUBLICATE. Lucrări ştiinţifice in extenso publicate în reviste de specialitate indexate ISI:
LISTA DE LUCRĂRI PUBLICATE Lucrări ştiinţifice in extenso publicate în reviste de specialitate indexate ISI: 1. Haba D, Teslaru S, Ungureanu D, Hodorog D, Alecu C, Benghiac AG, Zetu L, Ancuța C, Ancuța
More informationNational Horizon Scanning Centre. Saxagliptin (BMS ) for type 2 diabetes. April 2008
Saxagliptin (BMS 477118) for type 2 diabetes This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive statement
More informationCURRICULUM VITAE CURSURI URMATE:
CURRICULUM VITAE NUME: VLĂICULESCU PRENUME: MIHAELA VICTORIA DATA NAŞTERII: 24 Nov. 1969 ADRESA: Str. Voila nr 4, bl. 18, sc. 4, ap. 50, sector 4, Bucureşti TELEFON ACASĂ: 634.31.31, 0723 279420 STUDII:
More informationDoina-Andrada MIHAI CURRICULUM VITAE. Informaţii personale Data şi locul naşterii Nume purtat anterior căsătoriei Adresă , Bucureşti Bojin
CURRICULUM VITAE Doina-Andrada MIHAI Informaţii personale Data şi locul naşterii Nume purtat anterior căsătoriei Adresă E-mail 09.05.1974, Bucureşti Bojin Institutul Național de Diabet, Nutriţie şi Boli
More informationEvaluarea prin qpcr a diferentierii sensibilitatii la terapie si prognosticului in tumorile endocrine (RENET)
Contract finantare nr. 91/2012 Cod proiect: PN-II-PT-PCCA-2011-3.2.0623 Evaluarea prin qpcr a diferentierii sensibilitatii la terapie si prognosticului in tumorile endocrine (RENET) Real Time quantitative
More informationCurriculum vitae Europass
Curriculum vitae Europass Informaţii personale Nume / Prenume TAPALAGA GIANINA Adresă(e) B-l Eroilor nr 15,ap 8,etaj 3 Telefon(oane) Mobil: 0040 745263548 Fax(uri) E-mail(uri) tapalaga_gianina@yahoo.com
More informationSUNY Binghamton, B.S. Biochemistry, 5/80 SUNY Downstate Medical Center, M.D., 6/84
CURRICULUM VITAE RUSSELL D'AMBRA, M.D. July 2014 North Shore Diabetes & Endocrine Associates 3003 New Hyde Park Road Suite 201 New Hyde Park, New York 11042 516-327-0850 EDUCATION: POST-GRADUATE TRAINING:
More informationNUME: Maria-Magdalena Gurzun
NUME: Maria-Magdalena Gurzun ADRESĂ: Spitalul Universitar de Urgență Militar Central, Strada Plevnei, nr 134, telefon: 021.319.30.56 Fax: 021.312.18. DATE PERSONALE: Locul și data nașterii: 15 iulie, 1982,
More informationTable of Contents Section I Pituitary and Hypothalamus 1. Development of the Pituitary Gland 2. Divisions of the Pituitary Gland and Relationship to
Table of Contents Section I Pituitary and Hypothalamus 1. Development of the Pituitary Gland 2. Divisions of the Pituitary Gland and Relationship to the Hypothalamus 3. Blood Supply of the Pituitary Gland
More informationNEW DIABETES CARE MEDICATIONS
NEW DIABETES CARE MEDICATIONS James Bonucchi DO, ECNU, FACE Adult Medicine and Endocrinology Specialists Disclosures Speakers bureau Sanofi AZ BI Diabetes Diabetes cost ADA 2017 data Ever increasing disorder.
More informationIn compliance with the accrediting board policies, the American Diabetes Association requires the following disclosure to the participants:
In compliance with the accrediting board policies, the American Diabetes Association requires the following disclosure to the participants: Entity Activity Financial Consideration Comments Novo Nordisk
More informationStudy Design: Prospective, Multicenter randomized, parallel-group, double blind, placebo controlled study.
Brand Name: Farxiga Generic Name: Dapagliflozin Manufacturer: Astra-Zenica Drug Class 1,2 : Antidiabetic agent, SGLT2 Inhibitor Uses: Labeled Uses 1,2,3,4 : Improving glycemic control in adults with type
More informationHorizon Scanning Technology Summary. Liraglutide for type 2 diabetes. National Horizon Scanning Centre. April 2007
Horizon Scanning Technology Summary National Horizon Scanning Centre Liraglutide for type 2 diabetes April 2007 This technology summary is based on information available at the time of research and a limited
More informationA.K. Gitt, F. Towae, C. Juenger, A. Papp, R. Zahn, U. Zeymer, J. Senges For the STAR-Study-Group Herzzentrum Ludwigshafen, Germany
Impact of Interventional Versus Conservative Approach on 5-Year-Mortality of Patients With Stable Angina and Documented Coronary Artery Disease in Clinical Practice: Results of the STAR-Registry A.K. Gitt,
More informationSTEP THERAPY CRITERIA
CATEGORY DRUG CLASS BRAND NAME (generic) STEP THERAPY CRITERIA AMYLIN ANALOG: SYMLIN/SYMLINPEN (pramlintide acetate) ANTIDIABETIC AGENTS GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1): ADLYXIN (lixisenatide)
More information3/8/2011. Julie M. Sease, Pharm D, BCPS, CDE Associate Professor of Pharmacy Practice Presbyterian College School of Pharmacy
Summarize revisions to the 2011 American Diabetes Association clinical practice guidelines. Evaluate bromocriptine as a therapeutic option in the management of type 2 diabetes. Compare and contrast the
More informationAchieving and maintaining good glycemic control is an
Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE; Kathleen Wyne, MD, PhD, FACE, FNLA; Anthony Cannon,
More informationGLP-1 receptor agonists for type 2 diabetes currently available in the U.S.
GLP-1 receptor agonists for type 2 diabetes currently available in the U.S. GLP-1 agonists are a class of antidiabetic agents that mimic the actions of the glucagon-like peptide. GLP-1 is one of several
More informationMOA: Long acting glucagon-like peptide 1 receptor agonist
Alexandria Rydz MOA: Long acting glucagon-like peptide 1 receptor agonist Increases glucose dependent insulin secretion Decreases inappropriate glucagon secretion Increases β- cell growth and replication
More informationCurriculum Vitae Training in Systems Biology, Chalmers Technical University, Sweden Project title: Modelling Gut Microbiome in Obesity
Curriculum Vitae Full name: Dimiter Vassilev Dimitrov I. EDUCATION 2009 Training in Systems Biology, Chalmers Technical University, Sweden Project title: Modelling Gut Microbiome in Obesity 2005 Specialty
More informationAsociatia pentru Servicii Mobile de Ingrijire Paliativa in 2010
de Ingrijire Paliativa in 2010 Echipa SMIP Dr. Oana Donea, medic primar oncolog cu supraspecializare in ingrijire paliativa Luciana Negulescu, asistent medical principal Alina Lazar, asistent social Activitatile
More informationWhy is Earlier and More Aggressive Treatment of T2 Diabetes Better?
Blood glucose (mmol/l) Why is Earlier and More Aggressive Treatment of T2 Diabetes Better? Disclosures Dr Kennedy has provided CME, been on advisory boards or received travel or conference support from:
More informationNational Institute for Health and Care Excellence. Single Technology Appraisal (STA) Empagliflozin combination therapy for treating type 2 diabetes
National Institute for Health and Care Excellence Comment 1: the draft remit Single Technology Appraisal (STA) Empagliflozin combination therapy for treating type 2 diabetes Response to consultee and commentator
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal. Canagliflozin in combination therapy for treating type 2 diabetes
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal Canagliflozin in combination therapy for Final scope Remit/appraisal objective To appraise the clinical and cost effectiveness
More informationManagement of Type 2 Diabetes Cardiovascular Outcomes Trials Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas
Management of Type 2 Diabetes Cardiovascular Outcomes Trials 2018 Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas Speaker Disclosure Dr. Blevins has disclosed that he has received grant support
More informationPadurarilor, No 3, Timisoara (Romania) Sex Date of birth 06 July 1978 Nationality Romanian
Curriculum vitae PERSONAL INFORMATION George Puenea Padurarilor, No 3, Timisoara (Romania) +4 0722 438 747 george.puenea@yahoo.com Sex Date of birth 06 July 1978 Nationality Romanian PREFERRED JOB Higher
More informationCURRICULUM VITAE Nume Data şi locul nasterii Pregătire profesională Poziţii ocupate în prezent
CURRICULUM VITAE Nume: Vasiliu Octavian Data şi locul nasterii: 16.04.1974, Bucureşti Pregătire profesională -absolvent al Universităţii de Medicină şi Farmacie "Carol Davila" Bucureşti, Facultatea Medicină
More informationC U R I C U L U M V I T A E
C U R I C U L U M V I T A E A D I N A I O N A C ADRESA Loc de muncă Clinica Cardiologie II Departamentul de Cardiologie Universitatea de Medicină și Farmacie Victor Babeș Timișoara Institutul de Boli Cardiovasculare
More informationLa lezione dei trials di safety cardiovascolare. Edoardo Mannucci
La lezione dei trials di safety cardiovascolare Edoardo Mannucci Conflitti di interessi Negli ultimi due anni, E. Mannucci ha ricevuto compensi per relazioni e/o consulenze da: Abbott, AstraZeneca, Boehringer
More informationCURRICULUM VITAE. RESEARCH SITE NAME/ ADDRESS: Main Office: EDUCATION/TRAINING: BOARD CERTIFIED: BOARD CERTIFIED/ELIGIBLE NAME: TITLE:
CURRICULUM VITAE SIGNATURE: NAME: TITLE: Roy C, Springer, MD Principal Investigator DATE: DATE UPDATED: April 2016 RESEARCH SITE NAME/ ADDRESS: Main Office: MD Strategies Research Centers 6280 Jackson
More informationClinic of Dermatology, Clinical Hospital Sibiu
Curriculum vitae Europass Personal information First name(s) / Surname(s) Address(es) MARIA ROTARU Sibiu str. M. Costin No. 13, Sibiu, Romania Telephone (s) +40269215050 / 100 Mobile: +40724307495 Fax
More informationCurriculum vitae Europass
Curriculum vitae Europass Informaţii personale Nume / Prenume Adresă(e) LUNGU ADINA-ELENA BUCURESTI E-mail(uri) Naţionalitate(-tăţi) Data naşterii adina.lungu@yahoo.com Romana 28.07.1976,VIDELE,jud.TELEORMAN
More informationPACHETE DE PROMOVARE
PACHETE DE PROMOVARE Principalele coordonate ale Congresului Național de Neuropatie Diabetică și Picior Diabetic, cu participare internațională Neurodiab 2016 sunt: Speakeri de renume internațional Program
More informationLiraglutide (Victoza) in combination with basal insulin for type 2 diabetes
Liraglutide (Victoza) in combination with basal insulin for type 2 diabetes May 2011 This technology summary is based on information available at the time of research and a limited literature search. It
More informationSponsor / Company: Sanofi Drug substance(s): HOE901-U300 (insulin glargine) According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationIn prezent: Cercetator stiintiific grad III, medic primar gastroenterologie Centrul de Gastroenterologie si Hepatologie Institutul Clinic Fundeni
CURRICULUM VITAE Nume: VĂDAN ROXANA Data naşterii: 3.05. 1970 Locul naşterii: Bucureşti Adresa (spital): Centrul de Gastroenterologie si Hepatologie, Institutul Clinic Fundeni; Soseaua Fundeni nr 258,
More informationPHD THESIS A STUDY ON TUBERCULOUS PULMONARY INFILTRATES ASSOCIATED WITH MORBID, IMMUNOCOMPROMISED CONDITIONS
MINISTRY OF EDUCATION, RESEARCH AND YOUTH THE UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA PHD THESIS A STUDY ON TUBERCULOUS PULMONARY INFILTRATES ASSOCIATED WITH MORBID, IMMUNOCOMPROMISED CONDITIONS
More informationCREŢEANU GABRIELA ILEANA
INFORMAŢII PERSONALE CREŢEANU GABRIELA ILEANA Curriculum Vitae Adresa:Str. Gherasim Buliga, nr. 7, SUCEAVA, cod 720193, ROMÂNIA Telefon / Fax: 0040 0230 531915, Mobil : 0040 0722 707938 Data şi locul naşterii:
More informationNo Increased Cardiovascular Risk for Lixisenatide in ELIXA
ON ISSUES IN THE MANAGEMENT OF TYPE 2 DIABETES JUNE 2015 Coverage of data from ADA 2015, June 5 9 in Boston, Massachusetts No Increased Cardiovascular Risk for Lixisenatide in ELIXA First Cardiovascular
More informationCurrent Updates & Challenges In Managing Diabetes in CVD
Current Updates & Challenges In Managing Diabetes in CVD Preventive Cardiovascular Conference 2016 Instituit Jantung Negara 12 th November 2016 Nor Azmi Kamaruddin Diabetes Clinic Department of Medicine
More informationCANVAS Program Independent commentary
CANVAS Program Independent commentary Cliff Bailey Aston University, Birmingham, UK 2017 Disclosures and disclaimers Clifford J Bailey CJB has attended advisory boards, undertaken ad hoc consultancy, received
More informationCurriculum Vitae. I. Date autobiografice:
Curriculum Vitae I. Date autobiografice: Numele: CIRCO Prenumele: EDUARD Data nasterii: 26 Decembrie 1953 Locul nasterii: Apoldul de Sus- Judetul Sibiu Parinti: CIRCO LIDIA CIRCO GHENADIE II. Studii: Scoala
More information19-21 octombrie 2017 Hotel Ramada Parc/Ramada Plaza, București PACHETE DE PROMOVARE
19-21 octombrie 2017 Hotel Ramada Parc/Ramada Plaza, București PACHETE DE PROMOVARE 5 Principalele coordonate ale Congresului Național de Neuropatie Diabetică și Picior Diabetic, cu participare internațională
More informationSoliqua (insulin glargine and lixisenatide), Xultophy (insulin degludec and liraglutide)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.48 Subject: Insulin GLP-1 Combinations Page: 1 of 5 Last Review Date: September 15, 2017 Insulin GLP-1
More informationIndividualizing Care for Patients with Type 2 Diabetes
Individualizing Care for Patients with Type 2 Diabetes Disclosures Speaker: AstraZeneca, Novo Nordisk, BI/Lilly, Valeritas, Takeda Advisor: Tandem Diabetes, Sanofi Objectives Develop individualized approaches
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationLucrări ISI (in extenso)
Lucrări ISI (in extenso) 1. Daniela Călina, Anca Oana Docea, Lucica Roșu, Otilia Rogoveanu et al. Antimicrobial resistance development following surgical site infections. Molecular Medicine Reports, 2017.
More informationGuidelines to assist General Practitioners in the Management of Type 2 Diabetes. April 2010
Guidelines to assist General Practitioners in the Management of Type 2 Diabetes April 2010 Foreword The guidelines were devised by the Diabetes Day Centre in Beaumont Hospital in consultation with a number
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Dapagliflozin in combination therapy for the Final scope Remit/appraisal objective To appraise the clinical and
More informationIncretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
Incretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors Timothy Bailey, MD, FACE, CPI Director, AMCR Institute,
More informationClinical Research Institute HUCH Sponsored, fully signed Clinical Trial Agreements (except grants)
, fully signed Clinical Trial Agreements (except grants) Sponsor Full name of the Hospital clinic where the is details of the January x x January x NightstaRx Ltd A Randomised, Open Label, Outcomes-Assessor
More informationDr. Roxana-Cristina Mazilu medic specialist ORL. Experienta profesională. Formare. Experienţă practică
Dr. Roxana-Cristina Mazilu medic specialist ORL Experienta profesională August 2012: ocupatia/calificarea de formator (ANC) pentru cursuri de specialitate (audio-vestibular) Dec. 2006 - prezent: colaborare
More informationGlucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol
Glucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed
More informationBristol-Myers Squibb / AstraZeneca ADVICE dapagliflozin (Forxiga ) Indication under review: SMC restriction: Chairman, Scottish Medicines Consortium
Re-Submission dapagliflozin 5mg and 10mg film-coated tablets (Forxiga ) SMC No. (799/12) Bristol-Myers Squibb / AstraZeneca 07 February 2014 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationADA Analyst Presentation Saturday 9 th June
ADA Analyst Presentation Saturday 9 th June Carlo Russo Senior Vice-President & Albiglutide Team Leader, GSK Property of GlaxoSmithKline Agenda Welcome & introduction to the Harmony Clinical Programme
More informationUniversity of Medicine and Pharmacy Craiova. Faculty of Medicine. PhD THESIS ABSTRACT
University of Medicine and Pharmacy Craiova Faculty of Medicine PhD THESIS ABSTRACT STUDY OF THE CHANGES IN BONE MASS AND BONE METABOLISM MARKERS IN THYROTOXIC OSTEOPOROSIS. THERAPEUTIC IMPLICATIONS. Scientific
More informationScoala generala din cadrul Liceului Nicolae Balcescu,Cluj- Napoca Liceul Nicolae Balcescu,Cluj- Napoca.
NICOLCESCU PANTELIE Numele:NICOLCESCU Prenumele:PANTELIE Cetatenie:ROMANA Data si locul nasterii: 21.12.1965,Cluj-Napoca Starea civila:necasatorit Domiciliul:str.Muzicii nr.23,galati Telefon:0726693136
More informationSide Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors. Bryce Fukunaga PharmD April 25, 2018
Side Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors Bryce Fukunaga PharmD April 25, 2018 Objectives For each drug class: Identify the overall place in therapy Explain the mechanism of action
More informationChapter 15 ENDOCRINE AND METABOLIC IMPAIRMENT
Chapter 15 ENDOCRINE AND METABOLIC IMPAIRMENT Introduction This chapter provides criteria used to rate permanent impairment resulting from endocrine disorders and disorders of metabolism. The endocrine
More informationAl Cincilea Congres National de Medicina Integrativa
Prof. Dr Florin Bratila www.medicinacomplementarasialternativa.ro Prof. Dr Florin Bratila www.medicinacomplementarasialternativa.ro anunta organizarea/ announces Al Cincilea Congres National de Medicina
More informationInvokana (canagliflozin) NEW INDICATION REVIEW
Invokana (canagliflozin) NEW INDICATION REVIEW Introduction Brand name: Invokana Generic name: Canagliflozin Pharmacological class: Sodium-glucose cotransporter 2 (SGLT2) inhibitor Strength and Formulation:
More informationNavigating the New Options for the Management of Type 2 Diabetes
Navigating the New Options for the Management of Type 2 Diabetes Clinical Associate Professor Mark Kennedy Department of General Practice, University of Melbourne Chair, Primary Care Diabetes Society of
More informationCardiovascular Benefits of Two Classes of Antihyperglycemic Medications
Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications Nathan Woolever, Pharm.D., Resident Pharmacist Pharmacy Grand Rounds November 6 th, 2018 Franciscan Healthcare La Crosse, WI 2017
More informationSYNOPSIS. Administration: subcutaneous injection Batch number(s):
SYNOPSIS Title of the study: A randomized, double-blind, placebo-controlled, 2-arm parallel-group, multicenter 24-week study followed by an extension assessing the efficacy and safety of AVE0010 on top
More informationFARXIGA (dapagliflozin) Jardiance (empagliflozin) tablets. Synjardy (empagliflozin and metformin hydrochloride) tablets. GLUCOPHAGE* (metformin)
Type 2 Medications Drug Class How It Works Brand and Generic Names Manufacturers Usual Starting Dose The kidneys filter sugar and either absorb it back into your body for energy or remove it through your
More informationCURRICULUM VITAE (CV ) Institutul Oncologic Al.Trestiorean u Bucuresti. Sept sept Specialist oncologie medicala
CURRICULUM VITAE (CV ) 1. Nume: VOLOVAT 2. Prenume: CONSTANTIN 3. Data şi locul naşterii: 22 apr 1959, ROMAN, JUD.NEAMT 4. Cetăţenie: ROMANA 5. Stare civilă: CASATORIT 6. Studii: Instituţia Perioada: de
More informationA Practical Approach to the Use of Diabetes Medications
A Practical Approach to the Use of Diabetes Medications Juan Pablo Frias, M.D., FACE President, National Research Institute, Los Angles, CA Clinical Faculty, University of California, San Diego, CA OUTLINE
More informationUpdate on Cardiovascular Outcome Trials in Diabetes. Rury R. Holman, FMedSci NIHR Senior Investigator 11 th February 2013
Update on Cardiovascular Outcome Trials in Diabetes Rury R. Holman, FMedSci NIHR Senior Investigator 11 th February 2013 Residual Vascular Risk in People with Diabetes 2 Analyses based on 530,083 participants
More informationWayne Gravois, MD August 6, 2017
Wayne Gravois, MD August 6, 2017 Americans with Diabetes (Millions) 40 30 Source: National Diabetes Statistics Report, 2011, 2017 Millions 20 10 0 1980 2009 2015 2007 - $174 Billion 2015 - $245 Billion
More informationT max V d t 1/ hours 100 L 3 hours
Brand Name: Adlyxin Generic Name: lixisenatide Manufacturer: Sanofi-Aventis U.S. LLC 1 Drug Class: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist 2,3,4 Uses: Labeled Uses 1,2,3,4,5 : Type 2 diabetes
More informationCurriculum Vitae, Steven H. Reynolds, D.O. Steven H. Reynolds, D.O. Collaborative Neuroscience Network, LLC.
CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Alliance Director Tel. (916) 939-6696 Fax (208) 575-3169 Email: clinicaltrials@alliancesites.com AFFILIATIONS: Collaborative Neuroscience
More informationSYNOPSIS. Abbreviated Clinical Study Report. Study Code: RIMON_L_01031 Document Status: Synopsis V 2.1 Date: 16-Oct Title of the study:
SYNOPSIS Title of the study: Investigator(s): A 12-month multicentre, randomised, double-blind, placebo-controlled study with two parallel groups to assess the effects of rimonabant 20 mg in patients with
More informationUpdate on Therapies for Type 2 Diabetes: Angela D. Mazza, DO July 31, 2015
Update on Therapies for Type 2 Diabetes: 2015 Angela D. Mazza, DO July 31, 2015 Objectives To present the newer available therapies for the management of T2D To discuss the advantages and disadvantages
More informationNume: ZABARA. Studii: - Noiembrie 2012 promovarea examenului național de rezidențiat, specialitatea chirurgie generală
Nume: ZABARA Prenume: MIHAI LUCIAN E-mail: zabara_mihai@yahoo.com Telefon (fix/mobil): 0040742982486 Data naşterii: 28.07.1987 Locul naşterii: Tulcea Stare civilă: Căsătorit Nationalitate: Română Domiciliul
More informationTitlul tezei de doctorat: "PARTICULARITATI CLINICE, EVOLUTIVE SI DE TRATAMENT IN SARCOAMELE DE TESUTURI MOI LA COPIL"
DRAGOMIR MONICA DESIREE Conferentiar oncologie pediatrica A Teza de doctorat ( anul sustinerii, titlul) Titlu stiintific conferit in urma sustinerii tezei de doctorat la data de 26.04. 2000, in baza ordinului
More informationTHE IV-th NATIONAL SYMPOSIUM OF PEDIATRIC CARDIOLOGY octombrie 2009 TÎRGU MUREŞ
AL IV-lea SIMPOZION NAŢIONAL DE CARDIOLOGIE PEDIATRICĂ THE IV-th NATIONAL SYMPOSIUM OF PEDIATRIC CARDIOLOGY 15 17 octombrie 2009 TÎRGU MUREŞ Managementul cordului univentricular Hipertensiunea arterială
More informationUniversitate de Medicină și Farmacie Victor Babeș Timișoara Facultatea de Medicină, Lucrare de diplomă: 10 Medie de absolvire: 10
C U R I C U L U M V I T A E A D I N A I O N A C ADRESA Loc de muncă Clinica de Cardiologie Departamentul VI Cardiologie Institutul de Boli Cardiovasculare Timișoara Str. Gh. Adam 13A RO - 300310 Timișoara
More information10/27/2011. Challenges in Anti-diabetic Global Drug Development A Shift from Surrogate to Outcome Trials. Disclaimer
Challenges in Anti-diabetic Global Drug Development A Shift from Surrogate to Outcome Trials Eckhard Leifke, MD PhD Senior Medical Director Takeda Global Research Development Center, Inc. Presentation
More informationPramlintide & Weight. Diane M Karl MD. The Endocrine Clinic & Oregon Health & Science University Portland, Oregon
Pramlintide & Weight Diane M Karl MD The Endocrine Clinic & Oregon Health & Science University Portland, Oregon Conflict of Interest Speakers Bureau: Amylin Pharmaceuticals Consultant: sanofi-aventis Grant
More informationCurriculum Vitae, Joseph J. Savon, M.D.
CONTACT INFORMATION: Joseph J. Savon, M.D. Hassman Research Institute, LLC. 175 Cross Keys Road Centennial Center, Bldg. 300 B Berlin, NJ 08009 Site Selection and Information: Bobbie Theodore, Alliance
More informationCurriculum Vitae. Andreea Calin, MD. Born (Teodorescu) in 1977, Bucharest, Romania
Curriculum Vitae Andreea Calin, MD Born (Teodorescu) in 1977, Bucharest, Romania Education Graduated in Medicine from the University of Medicine and Pharmacy Carol Davila Bucharest, Romania (2001). Resident
More informationPeter Stein, MD Janssen Research and Development
New Agents and Technologies in the Pipeline for the Treatment of Patients with Diabetes Peter Stein, MD Janssen Research and Development Agents in Phase 3 Development for T2DM Long-acting GLP-1 analogues
More informationSubsequent New Drugs Division. M/s.Troikaa. M/s. Olive Healthcare. Biological Division. M/s. Wockhardt Ltd. Global Clinical Trial Division
: The34 th SEC (Endocrinology & Metabolism) meeting held on 25.04.2017 at CDSCO HQ New Delhi and recommended the following: Age Subsequent New Drugs Division 1 12-146/2016-DC (Pt- Zim-Snd) Vitamin D3 (Cholecalciferol)
More informationTHE PROSPECTIVE ANALYSIS OF MORTALITY IN TYPE 2 DIABETES SUBJECTS IN BUCHAREST, ROMANIA
THE PROSPECTIVE ANALYSIS OF MORTALITY IN TYPE 2 DIABETES SUBJECTS IN BUCHAREST, ROMANIA SORIN IOACARA *, SORIN V. SABAU **, CRISTIAN SERAFINCEANU and CONSTANTIN IONESCU-TÎRGOVIŞTE * * N. Paulescu National
More informationHelp the Heart. An Update on GLP-1 Agonists and SGLT2 Inhibitors. Tara Hawley, PharmD PGY1 Pharmacy Resident Mayo Clinic Health System Eau Claire
Help the Heart An Update on GLP-1 Agonists and SGLT2 Inhibitors Tara Hawley, PharmD PGY1 Pharmacy Resident Mayo Clinic Health System Eau Claire Mayo Clinic Grand Rounds May 16, 2017 2017 MFMER slide-1
More informationCURRICULUM VITAE PERSONAL INFORMATION
CURRICULUM VITAE PERSONAL INFORMATION Name: Mihai Raul Popescu Place of Birth : May 6 nd 1963, Craiova, Romania Marital status: Married, 2 child Address: Craiova 400421, street Barati, no.1 Telephone:
More informationErtugliflozin (Steglatro ) 5 mg daily. May increase to 15 mg daily. Take in the morning +/- food. < 60: Do not initiate; discontinue therapy
Sodium-glucose Cotransporter-2 (SGLT2) s Inhibit SGLT in proximal renal tubules, reducing reabsorption of filtered glucose from tubular lumen Lowers renal threshold for glucose à increase urinary excretion
More informationPREVALENCE OF FRAILTY SYNDROME AMONG TYPE 2 DIABETES MELLITUS ELDERLY PATIENTS
Rom. J. Gerontol. Geriatr., 2018, Vol. 7, No. 1, p. 25-31 PREVALENCE OF FRAILTY SYNDROME AMONG TYPE 2 DIABETES MELLITUS ELDERLY PATIENTS Raluca Nacu 1, Anna Marie Herghelegiu 1,2, Gabriel Ioan Prada 1,2
More informationDOCTORATE THESIS THE STUDY OF CEREBRAL VASCULAR AND NEUROPHYSIOLOGIC CEREBRAL MANIFESTATIONS ON A GROUP OF PACIENTS SUFFERING FROM CHRONIC ETHANOLISM
UNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA MEDICINE FACULTY DOCTORATE THESIS THE STUDY OF CEREBRAL VASCULAR AND NEUROPHYSIOLOGIC CEREBRAL MANIFESTATIONS ON A GROUP OF PACIENTS SUFFERING FROM CHRONIC ETHANOLISM
More information23-Aug-2011 Lixisenatide (AVE0010) - EFC6014 Version number: 1 (electronic 1.0)
SYNOPSIS Title of the study: A randomized, double-blind, placebo-controlled, parallel-group, multicenter 24-week study followed by an extension assessing the efficacy and safety of AVE0010 on top of metformin
More informationCurrent Status of Incretin Based Therapies in Type 2 Diabetes
Current Status of Incretin Based Therapies in Type 2 Diabetes DR.M.Mukhyaprana Prabhu Professor of Internal Medicine Kasturba Medical College, Manipal, Manipal University, India 2 nd International Endocrine
More informationThe Pennine Acute Hospitals NHS Trust Performance in delivering clinical research Reporting period 1 October 2017 to 30 September 2018
The Pennine Acute Hospitals NHS Trust Performance in delivering clinical research Reporting period 1 October 2017 to 30 September 2018 REC reference IRAS reference Name of trial Target number of? Minimum
More informationSponsor: Sanofi Drug substance(s): Lantus /insulin glargine. Study Identifiers: U , NCT Study code: LANTUL07225
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor: Sanofi Drug substance(s):
More informationCENTER FOR CLINICAL TRIALS St. Luke s Medical Center. Ongoing Clinical Trials DEPARTMENT OF MEDICINE (24)
CENTER FOR CLINICAL TRIALS St. Luke s Medical Center Ongoing Clinical Trials DEPARTMENT OF MEDICINE (24) Arthritis TITLE : A Randomized, Double Blind, Parallel-Group Study Of Cardiovascular Safety In Osteoarthritis
More informationDu gusts is megl che one. Edoardo Mannucci
Du gusts is megl che one Edoardo Mannucci Conflitti di interessi Negli ultimi due anni, E. Mannucci ha ricevuto compensi per relazioni e/o consulenze da: Abbott, AstraZeneca, Boehringer Ingelheim, Eli
More information